Have a personal or library account? Click to login
Decoding Dystonia in Autoimmune Disorders: A Scoping Review Cover

Decoding Dystonia in Autoimmune Disorders: A Scoping Review

Tremor and Other Hyperkinetic Movements
Volume 14 (2024): Issue 1
By: Debayan Dutta and  Ravi Yadav  
Open Access
|Dec 2024

References

  1. 1Jinnah HA, Hess, EJ. Evolving Concepts in the Pathogenesis of Dystonia. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696051/.
    Back to article
  2. 2Kaji R, Bhatia K, Graybiel AM. Pathogenesis of Dystonia: is it of cerebellar or basal ganglia origin? J Neurol Neurosurg Psychiatry. 2018; 89(5): 488–92. DOI: 10.1136/jnnp-2017-316250
    Back to article
  3. 3Balint B, Vincent A, Meinck HM, Irani SR, Bhatia KP. Movement disorders with neuronal antibodies: Syndromic approach, genetic parallels and pathophysiology. Brain. 2018; 141(1): 13–36. DOI: 10.1093/brain/awx189
    Back to article
  4. 4Arksey H, O’Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol Theory Pract. 2005; 8(1): 19–32. DOI: 10.1080/1364557032000119616
    Back to article
  5. 5Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018; 169(7): 467–73. DOI: 10.7326/M18-0850
    Back to article
  6. 6Graus F, Titulaer MJ, Balu R, Benseler SM, Bien CG, Cellucci T, et al. Encephalitis autoimmune diagnosis adult. Lancet Neurol – NIH. 2016; 15(4): 391–404. DOI: 10.1016/S1474-4422(15)00401-9
    Back to article
  7. 7Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis in Children and Adolescents NIH Public Access Author Manuscript. Ann Neurol [Internet]. 2009; 66(1): 11–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826225/pdf/nihms-173684.pdf. DOI: 10.1002/ana.21756
    Back to article
  8. 8Balint B. Autoimmune Movement Disorders in Adults. Pract Neurol. 2020; (September).
    Back to article
  9. 9Varley JA, Webb AJS, Balint B, Fung VSC, Sethi KD, Tijssen MAJ, et al. The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: An expert video-rating study. J Neurol Neurosurg Psychiatry. 2019; 90(6): 724–6. DOI: 10.1136/jnnp-2018-318584
    Back to article
  10. 10Duan B-C, Weng W-C, Lin K-L, Wong LC, Li S-T, Hsu M-H, et al. Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis A nationwide study in Taiwan. 2016 [cited 2023 Nov 4]. DOI: 10.1097/MD.0000000000004365
    Back to article
  11. 11Anadani BN. Anti-N-Methyl d Aspartate Receptor Encephalitis. 2020; (September): 52–5.
    Back to article
  12. 12Haq AU, Nabi D, Alam M, Ullah SA. The Spectrum of Movement Disorders in Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis Both in Children and Adults: An Experience From a Single Tertiary Care Center. Cureus [Internet]. 2021 Dec 13 [cited 2023 Jun 23]; 13(12). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752382/. DOI: 10.7759/cureus.20376
    Back to article
  13. 13Kleinig TJ, Thompson PD, Matar W, Duggins A, Kimber TE, Morris JG, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord. 2008; 23(9): 1256–61. DOI: 10.1002/mds.22073
    Back to article
  14. 14Poloni C, Korff CM, Ricotti V, King MD, Perez ER, Mayor-Dubois C, et al. Severe childhood encephalopathy with dyskinesia and prolonged cognitive disturbances: Evidence for anti-N-methyl-d-aspartate receptor encephalitis. Dev Med Child Neurol. 2010; 52(5). DOI: 10.1111/j.1469-8749.2009.03542.x
    Back to article
  15. 15Waller SE, Williams L, Lee AYS, Lin M-W, McCusker E, Morales-Briceño H, et al. Isolated Craniocervical Dystonia Without Initial Neuropsychiatric Manifestations Associated with NMDA-Receptor Antibodies. Mov Disord Clin Pract [Internet]. 2023 Apr 9 [cited 2023 Nov 5]; 10(4): 680–2. Available from: https://onlinelibrary.wiley.com/. DOI: 10.1002/mdc3.13517
    Back to article
  16. 16Bhansali S, Chatterjee CS, Siddique U, Basu P, Choudhury S, Tiwari M, et al. Cervical Dystonic Tremor and Dysphonia—Rare Presentation of Anti–N-Methyl-D-Aspartate Encephalitis and Its Management. Mov Disord Clin Pract. 2023; 10(4): 683–6. DOI: 10.1002/mdc3.13579
    Back to article
  17. 17Rubio-Agustí I, Dalmau J, Sevilla T, Burgal M, Beltrán E, Bataller L. Isolated hemidystonia associated with NMDA receptor antibodies. Mov Disord. 2011; 26(2): 351–2. DOI: 10.1002/mds.23315
    Back to article
  18. 18Tzoulis C, Vedeler C, Haugen M, Storstein A, Tran GT, Gjerde IO, et al. Progressive striatal necrosis associated with anti-NMDA receptor antibodies. BMC Neurol. 2013; 13: 2–5. DOI: 10.1186/1471-2377-13-55
    Back to article
  19. 19Mohammad SS, Fung VSC, Grattan-Smith P, Gill D, Pillai S, Ramanathan S, et al. Movement disorders in children with anti-NMDAR Encephalitis and other autoimmune encephalopathies. Mov Disord. 2014; 29(12): 1539–42. DOI: 10.1002/mds.25999
    Back to article
  20. 20Granata T, Matricardi S, Ragona F, Freri E, Zibordi F, Andreetta F, et al. Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders. 2018 [cited 2023 Nov 7]; DOI: 10.1016/j.ejpn.2018.01.012
    Back to article
  21. 21Kim SW, Lee HS, Lee PH, Choi S-A. Anti-NMDA Receptor Encephalitis with a Favorable Prognosis Despite Delayed Treatment Due to Longstanding Psychiatric Symptoms CLINICAL PRACTICE. 2014 [cited 2023 Nov 6]; Available from: https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.12095.
    Back to article
  22. 22Joshi SP, Thomas M, Yoganathan S, Danda S, Chandran M, Jasper A. Clinico Etiological Spectrum and Functional Outcomes of Children with Pre Status Dystonicus and Status Dystonicus (SD): A Descriptive Study. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394458/pdf/AIAN-26-268.pdf. DOI: 10.4103/aian.aian_660_22
    Back to article
  23. 23Matsumoto H, Hashida H, Takahashi Y. Dystonic Seizures and Intense Hyperperfusion of the Basal Ganglia in a Patient with Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Case Rep Neurol [Internet]. 2017 [cited 2023 Nov 4]; 9(3): 272. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836200/. DOI: 10.1159/000484200
    Back to article
  24. 24Son DK, Cho SM, Ryu HU, Shin BS, Kang HG. Anti-NMDAR encephalitis with bilateral basal ganglia MRI lesions at a distance of time: a case report. BMC Neurol [Internet]. 2022; 22(1): 1–4. DOI: 10.1186/s12883-022-02652-y
    Back to article
  25. 25Nguyen L, Wang C. Anti-NMDA Receptor Autoimmune Encephalitis: Diagnosis and Management Strategies. Int J Gen Med. 2023; 16(December 2022): 7–21. DOI: 10.2147/IJGM.S397429
    Back to article
  26. 26Takeuchi H, Shimizu F, Yoshikura N, Shi J, Tian J, Teng Y, et al. Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review. Front Neurol | www.frontiersin.org [Internet]. 2022 [cited 2023 Dec 2]; 1: 791014. Available from: www.frontiersin.org
    Back to article
  27. 27Wang M, Cao X, Liu Q, Ma W, Guo X, Liu X. Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat. 2017; 13: 1589–96. DOI: 10.2147/NDT.S136723
    Back to article
  28. 28Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain [Internet]. 2013 [cited 2023 Dec 2]; 136(Pt 10): 3151–62. Available from: https://pubmed.ncbi.nlm.nih.gov/24014519/.
    Back to article
  29. 29Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: A diagnostic clue of anti-LGI1 encephalitis? Neurology [Internet]. 2011 Apr 4 [cited 2023 Dec 2]; 76(15): 1355. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090064/.
    Back to article
  30. 30Jagtap SA, Aurangabadkar K, Joshi A, Chitnis S, Rathod M, Khade H. LGI1 Encephalitis: Autoimmune Epilepsy or Movement Disorder. Ann Indian Acad Neurol. 2023; 26(5): 831–4. DOI: 10.4103/aian.aian_626_23
    Back to article
  31. 31Qiao S, Wu HK, Liu LL, Wang ML, Zhang RR, Han T, et al. Clinical features and long-term outcomes of anti-leucine-rich glioma-inactivated 1 encephalitis: A multi-center study. Neuropsychiatr Dis Treat. 2021; 17: 203–12. DOI: 10.2147/NDT.S292343
    Back to article
  32. 32van Sonderen A, Schreurs MWJ, Wirtz PW, Sillevis Smitt PAE, Titulaer MJ. From VGKC to LGI1 and Caspr2 Encephalitis: The evolution of a disease entity over time. Autoimmun Rev [Internet]. 2016 Oct 1 [cited 2023 Dec 2]; 15(10): 970–4. Available from: https://pubmed.ncbi.nlm.nih.gov/27485013/.
    Back to article
  33. 33Gao L, Liu A, Zhan S, Wang L, Li L, Guan L, et al. Clinical characterization of autoimmune LGI1 antibody limbic encephalitis. Epilepsy Behav [Internet]. 2016 Mar 1 [cited 2023 Dec 2]; 56: 165–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26896820/.
    Back to article
  34. 34Kim H, Lim Y, Kim K. Anti-Ri-Antibody-Associated Paraneoplastic Syndrome in a Man with Breast Cancer Showing a Reversible Pontine Lesion on MRI. 2009; 151–2. DOI: 10.3988/jcn.2009.5.3.151
    Back to article
  35. 35Simard C, Vogrig A, Joubert B, Muñiz-castrillo S. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. 2020; 0: 1–9. DOI: 10.1212/NXI.0000000000000699
    Back to article
  36. 36Bekircan-kurt CE, Temucin ÇM, Elibol B, Saka E. Parkinsonism and Related Disorders ‘Jaw clenching’ in anti-Ri – Antibody-associated paraneoplastic syndrome. Park Relat Disord [Internet]. 2013; 19(1): 132–3. DOI: 10.1016/j.parkreldis.2012.05.013
    Back to article
  37. 37Other T, Mov H, Sh O, Ky L, Jh I. Jaw Dystonia and Myelopathy: Paraneoplastic Manifestations of Breast Malignancy with anti - Ri/ANNA - 2 Antibody. 2021; 24(5): 4–6. DOI: 10.4103/aian.AIAN_920_20
    Back to article
  38. 38Duncan PR, Baehring JM, Matsumoto JY, Lennon VA. Paraneoplastic Jaw Dystonia and Laryngospasm With Antineuronal Nuclear Autoantibody Type 2 (Anti-Ri). 2016; 67(9): 1109–15.
    Back to article
  39. 39Tisavipat N, Chang BK, Ali F, Pittock SJ, Kammeyer R, Declusin A, et al. Subacute Horizontal Diplopia, Jaw Dystonia, and Laryngospasm. Neurol Neuroimmunol neuroinflammation. 2023; 10(4). DOI: 10.1212/NXI.0000000000200128
    Back to article
  40. 40Tazi R, Salimi Z, Fadili H, Aasfara J, Hazim A. Anti-Ri-Associated Paraneoplastic Neurological Syndrome Revealing Breast Cancer: A Case Report Case Presentation. 2022; 14(1): 5–9. DOI: 10.7759/cureus.21106
    Back to article
  41. 41Bhatti MT. Bilateral horizontal gaze palsy due to Anti-IgLON5 disease. Am J Ophthalmol Case Reports [Internet]. 2022; 27(March): 101574. DOI: 10.1016/j.ajoc.2022.101574
    Back to article
  42. 42Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody. Neurol Neuroimmunol NeuroInflammation. 2017; 4(5): 1–8. DOI: 10.1212/NXI.0000000000000385
    Back to article
  43. 43Shambrook P, Hesters A, Marois C, Zemba D, Servan J, Gaymard B, et al. Delayed Benefit From Aggressive Immunotherapy in Waxing and Waning Anti-IgLON5 Disease. Neurol Neuroimmunol NeuroInflammation. 2021; 8(4): 1–4. DOI: 10.1212/NXI.0000000000001009
    Back to article
  44. 44Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y, et al. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology. 2021; 97(14): E1367–81. DOI: 10.1212/WNL.0000000000012639
    Back to article
  45. 45Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016; 31(5): 762–4. DOI: 10.1002/mds.26608
    Back to article
  46. 46Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, et al. Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry. 2021; 92(6): 645–54. DOI: 10.1136/jnnp-2020-325275
    Back to article
  47. 47Mentreddi AP, Chitnis S, Khemani P. (Dallas, TX US). A unique phenotype associated with anti-GAD antibodies. Available from: https://www.mdsabstracts.org/abstract/a-unique-phenotype-associated-with-anti-gad-antibodies/.
    Back to article
  48. 48Kauppila AL, Coelho M, Franco AC, Teodoro T, Peralta AR, Bentes C, et al. Anti–Glutamic Acid Decarboxylase Encephalitis Presenting With Choreo-Dystonic Movements and Coexisting Electrographic Seizures. Mov Disord Clin Pract. 2019; 6(6): 483–5. DOI: 10.1002/mdc3.12800
    Back to article
  49. 49Sunwoo JS, Chu K, Byun JI, Moon J, Lim JA, Kim TJ, et al. Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders. J Neuroimmunol [Internet]. 2016; 290: 15–21. DOI: 10.1016/j.jneuroim.2015.11.012
    Back to article
  50. 50McKeon A, Tracy JA. GAD65 Neurological Autoimmunity. Available from: https://sci-hub.se/https://doi.org/10.1002/mus.25565.
    Back to article
  51. 51Markakis I, Alexiou E, Xifaras M, Gekas G, Rombos A. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg. 2008; 110(6): 619–21. DOI: 10.1016/j.clineuro.2008.03.005
    Back to article
  52. 52No Title. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764933/pdf/AIAN-25-935b.pdf.
    Back to article
  53. 53Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006; 81(9): 1207–14. DOI: 10.4065/81.9.1207
    Back to article
  54. 54Zhang C, Dai Y, Han B, Peng J, Ma J, Tang Q, et al. A Case of Anti-GAD 65 Autoimmune Encephalitis Associated with Focal Segmental Stiff-Person Syndrome. Brain Sci. 2023; 13(2). DOI: 10.3390/brainsci13020369
    Back to article
  55. 55Chia NH, McKeon A, Dalakas MC, Flanagan EP, Bower JH, Klassen BT, et al. Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria. Ann Clin Transl Neurol. 2023; 10(7): 1083–94. DOI: 10.1002/acn3.51791
    Back to article
  56. 56Rakocevic G, Floeter MK. Autoimmune stiff person syndrome and related myelopathies: Understanding of electrophysiological and immunological processes. Muscle and Nerve. 2012; 45(5): 623–34. DOI: 10.1002/mus.23234
    Back to article
  57. 57Pettingill P, Kramer HB, Coebergh JA, Pettingill R, Maxwell S, Nibber A, et al. Antibodies to GABAA receptor α1 and γ2 subunits: Clinical and serologic characterization. Neurology. 2015; 84(12): 1233–41. DOI: 10.1212/WNL.0000000000001326
    Back to article
  58. 58Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Artigues MIB, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017; 88(11): 1012–20. DOI: 10.1212/WNL.0000000000003713
    Back to article
  59. 59Guo CY, Gelfand JM, Geschwind MD. Anti-gamma-aminobutyric acid receptor type A encephalitis: a review. Curr Opin Neurol. 2020; 33(3): 372–80. DOI: 10.1097/WCO.0000000000000814
    Back to article
  60. 60Vacchiano V, Giannoccaro MP, Rinaldi R, Guarino M, Liguori R. Movement Disorders Associated with GABAA Receptor Encephalitis: A Video Case Report. Mov Disord Clin Pract. 2020; 7(6): 681–3. DOI: 10.1002/mdc3.12987
    Back to article
  61. 61do Valle DA, Ferreira Santos MLS, Spinosa MJ, Telles BA, Prando C, Cordeiro ML. GABAA receptor encephalitis associated with human parvovirus B19 virus infection.
    Back to article
  62. 62O’Connor K, Waters P, Komorowski L, Zekeridou A, Guo CY, Mgbachi VC, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol NeuroInflammation. 2019; 6(3): 0–6. DOI: 10.1212/NXI.0000000000000552
    Back to article
  63. 63Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012; 135(11): 3453–68. DOI: 10.1093/brain/aws256
    Back to article
  64. 64Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: Clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017; 30(3): 334–44. DOI: 10.1097/WCO.0000000000000443
    Back to article
  65. 65Develop Med Child Neuro – 2007 – Dale – Post-streptococcal autoimmune Dystonia with isolated bilateral striatal necrosis.pdf.
    Back to article
  66. 66Ancona C, Masenello V, Tinnirello M, Toscano LM, Leo A, La Piana C, et al. Autoimmune Encephalitis and Other Neurological Syndromes With Rare Neuronal Surface Antibodies in Children: A Systematic Literature Review. Front Pediatr. 2022; 10(April): 1–12. DOI: 10.3389/fped.2022.866074
    Back to article
  67. 67Lai M, Li Y, Luo D, Xu J, Li J. Dopamine-2 receptor antibody encephalitis presenting as pure tongue-biting in a tourette syndrome patient: a case report. BMC Psychiatry [Internet]. 2022; 22(1): 1–8. DOI: 10.1186/s12888-021-03683-4
    Back to article
  68. 68F.1 A, O.1 P, V.2 B, F.2 C, N. M, 3, et al. Anti-dopamine D2 receptor antibodies in chronic tic disorders: Potential link to fluctuations of tic severity. Available from: https://discovery.ucl.ac.uk/id/eprint/10104967/3/Schrag_anti-D2R%20%20paper%20_%20revised%20Oct%203%202019.pdf
    Back to article
  69. 69Liu Y, Hao X, Zhou D, Hong Z. Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies. Neurol Neuroimmunol NeuroInflammation. 2022; 9(4): 2–5. DOI: 10.1212/NXI.0000000000001172
    Back to article
  70. 70Pawela C, Brunsdon RK, Williams TA, Porter M, Dale RC, Mohammad SS. The neuropsychological profile of children with basal ganglia encephalitis: a case series. Dev Med Child Neurol. 2017; 59(4): 445–8. DOI: 10.1111/dmcn.13351
    Back to article
  71. 71Dai X, Kuang L, Feng L, Yi X, Tang W, Liao Q, et al. Anti-Dopamine Receptor 2 Antibody-Positive Encephalitis in Adolescent. Front Neurol. 2020; 11(June): 1–4. DOI: 10.3389/fneur.2020.00471
    Back to article
  72. 72Marinas JE, Matveychuk D, Dursun SM, Baker GB. Neuroimmunological antibody-mediated encephalitis and implications for diagnosis and therapy in neuropsychiatry. Acta Neuropsychiatr. 2019. DOI: 10.1017/neu.2019.50
    Back to article
  73. 73Zekeridou A, Kryzer T, Guo Y, Hassan A, Lennon V, Lucchinetti CF, et al. Phosphodiesterase 10 A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity. Neurology. 2019; 93(8): e815–22. DOI: 10.1212/WNL.0000000000007971
    Back to article
  74. 74Degapudi S, Khumar N, Velusamy S, Lakshmi Narasimhan R, Shrivarthan R, Maheshwari U, et al. Atypical neurological syndromes in anti-MA2 associated Encephalitis: Two case reports. J Neurol Sci [Internet]. 2023; 455: 121199. DOI: 10.1016/j.jns.2023.121199
    Back to article
  75. 75Shiraishi 1 W, Iwanaga I, Yamamoto A. A case of an anti-Ma2 antibody-positive patient presenting with variable CNS symptoms mimicking multiple system atrophy with a partial response to immunotherapy] [Article in Japanese]. DOI: 10.5692/clinicalneurol.55.96
    Back to article
  76. 76Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J, et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol. 2002; 51(5): 621–5. DOI: 10.1002/ana.10179
    Back to article
  77. 77Waheed W, Boyd J, Khan F, Mount SL, Borden NM, Tandan R. Double trouble: para-neoplastic anti-PCA-2 and CRMP-5-mediated small fibre neuropathy followed by chorea associated with small cell lung cancer and evolving radiological features. BMJ Case Rep. 2016; 2016. DOI: 10.1136/bcr-2016-215158
    Back to article
  78. 78Wang S, Hou H, Tang Y, Zhang S, Wang G, Guo Z, et al. An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes. Neural Regen Res. 2023; 18(11): 2357–64. DOI: 10.4103/1673-5374.371400
    Back to article
  79. 79Neurology Clinical Neurosc – 2023 – Zveik – Myelin oligodendrocyte glycoprotein antibody-associated disease presenting.pdf.
    Back to article
  80. 80Sa M, Thornton R, Chong WK, Kaliakatsos M, Hacohen Y. Paediatric MOG antibody–associated ADEM with complex movement disorder: A case report. Mult Scler J. 2019; 25(1): 125–8. DOI: 10.1177/1352458518786074
    Back to article
  81. 81Khan TR, Waugh JL, Wang C. Anti-Myelin Oligodendrocyte Glycoprotein (MOG) antibody disease presenting with severe dystonia. Available from: https://www.sciencedirect.com/science/article/pii/S2667257X2100036X?via%3Dihub.
    Back to article
  82. 82Sun Y, Tao JX, Han X, Wang X, Zhu Y, Lian Y, et al. Clinical features and brain MRI volumetric changes in anti-mGluR5 encephalitis. Ann Clin Transl Neurol. 2023; 10(8): 1407–16. DOI: 10.1002/acn3.51831
    Back to article
  83. 83Spatola M, Sabater L, Planagumà J, Martínez-Hernandez E, Armangué T, Prüss H, et al. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Neurology. 2018; 90(22): e1964–72. DOI: 10.1212/WNL.0000000000005614
    Back to article
  84. 84Shi K, Zhao H, Li Y, Li X, Chen W. Anti-metabolic glutamate receptor 5 encephalitis with gangliocytoma: a case and review of the literature. BMC Neurol [Internet]. 2024; 24(1): 1–6. DOI: 10.1186/s12883-024-03528-z
    Back to article
  85. 85Guo K, Liu X, Gong X, Li A, Liu Y, Li X, et al. Autoimmune encephalitis with mGluR5 antibodies: A case series from China and review of the literature. Front Immunol. 2023; 14(March): 1–11. DOI: 10.3389/fimmu.2023.1146536
    Back to article
  86. 86Hoshina Y, Wong KH, Galli J, Bacharach R, Klein J, Lebiedz-Odrobina D, et al. Neurologic involvement in seronegative primary Sjögren’s syndrome with positive minor salivary gland biopsy: a single-center experience. Front Neurol. 2023; 14(June): 1–6. DOI: 10.3389/fneur.2023.1174116
    Back to article
  87. 87Menozzi E, Mulroy E, Akbarian-Tefaghi L, Bhatia KP, Balint B. Movement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations. Park Relat Disord [Internet]. 2021; 88(May): 116–28. DOI: 10.1016/j.parkreldis.2021.05.026
    Back to article
  88. 88Kargiotis O, Papathanasopoulos P, Efstathios T, Yiannopoulos G, Andonopoulos AP. Bilateral blepharospasm as the presenting symptom of Sjögren’s syndrome with evidence of central nervous system involvement. Acta Neuropsychiatr. 2010; 22(5): 263–5. DOI: 10.1111/j.1601-5215.2010.00485.x
    Back to article
  89. 89Mantero V, Balgera R, Rigamonti A, Basso F, Salmaggi A. Efficacy of high dose methylprednisolone in a patient with cervical dystonia and blepharospasm and Sjögren’s syndrome. Neurol Sci. 2015; 36(5): 803–4. DOI: 10.1007/s10072-014-1907-1
    Back to article
  90. 90Papageorgiou SG, Kontaxis T, Bonakis A, Kalfakis N. Orofacial dystonia related to Sjogren’s syndrome. Clin Rheumatol. 2007; 26(10): 1779–81. DOI: 10.1007/s10067-006-0519-4
    Back to article
  91. 91Li X, Su L, Zhao Y. Sjogren’s syndrome meets Meige’s syndrome. Available from: https://www.jni-journal.com/article/S0165-5728(23)00250-3/fulltext.
    Back to article
  92. 92Ararat K, Berrios I, Hannoun A, Ionete C. Case of primary Sjogren’s syndrome preceded by dystonia. BMJ Case Rep. 2018; 2018: 1–5. DOI: 10.1136/bcr-2017-223468
    Back to article
  93. 93Jabbari B, Salardini A. Painful Tonic/Dystonic Spasms in Sjogren’s Syndrome. 1999; 14(5): 860–4. DOI: 10.1002/1531-8257(199909)14:5<;860::AID-MDS1024>3.0.CO;2-8
    Back to article
  94. 94Aggarwal A, Warren JE, Warren JD, Thompson PD. Facial reflex hyperexcitability in geniospasm suggests a brainstem origin. Mov Disord. 2009; 24(5): 783–4. DOI: 10.1002/mds.22454
    Back to article
  95. 95Fearon C, Rawal S, Olszewska D, Alcaide-Leon P, Kern DS, Sharma S, et al. Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders. Mov Disord Clin Pract. 2022; 9(3): 311–25. DOI: 10.1002/mdc3.13415
    Back to article
  96. 96García-Moreno JM, Chacón J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: Case report and review of the literature. Mov Disord. 2002; 17(6): 1329–35. DOI: 10.1002/mds.10288
    Back to article
  97. 97Wu K, Christodoulou L, Siddiqui A, D’Cruz D, Andrews T. Bilateral reversible basal ganglia changes associated with dystonia and hemifacial spasms in central nervous system lupus. Quant Imaging Med Surg [Internet]. 2015; 5(6): 928–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26807375%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4700240.
    Back to article
  98. 98Ramcharan K, Abdool K, Persad N, Dyaanand H. Movement disorders in systemic lupus erythematosus and antiphospholipid syndrome – A video presentation. BMJ Case Rep. 2015; 2015: 2014–5. DOI: 10.1136/bcr-2014-209201
    Back to article
  99. 99Romba M, Wang Y, Hu SC, Khot S. Jaw Dystonia and Reversible Basal Ganglia Changes as an Initial Presentation of Systemic Lupus Erythematosus. Neurohospitalist. 2018; 8(1): 31–4. DOI: 10.1177/1941874417698323
    Back to article
  100. 100lim1998.pdf.
    Back to article
  101. 101Goswami JN, Roy S. Department of Pediatrics, Army Hospital (Research & Referral), New Delhi I. Writer’s Cramp and Psychosis: An Atypical Presentation of Systemic Lupus Erythematosus. Available from: https://www.indianpediatrics.net/mar2021/mar-289-290.htm. DOI: 10.1007/s13312-021-2179-5
    Back to article
  102. 102Filatova EG, Alekseev V, Erdes S, David O. ADULT ONSET DYSTONIA OF THE FOOT AS A PRESENTING SYMPTOM OF SYSTEMIC LUPUS ERYTHEMATOSUS. Available from: https://www.researchgate.net/publication/284609290_P2678_ADULT_ONSET_DYSTONIA_OF_THE_FOOT_AS_A_PRESENTING_SYMPTOM_OF_SYSTEMIC_LUPUS_ERYTHEMATOSUS_P2679_NEUROPATHIC_PAIN_IN_PATIENTS_WITH_RHEUMATOID_ARTHRITIS.
    Back to article
  103. 103Rajagopalan N, Humphrey PRD, Bucknall RC. Torticollis and blepharospasm in systemic lupus erythematosus. Mov Disord. 1989; 4(4): 345–8. DOI: 10.1002/mds.870040410
    Back to article
  104. 104Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord. 1987; 2(3): 159–63. DOI: 10.1002/mds.870020303
    Back to article
  105. 105Man YL, Sanna G. Neuropsychiatric Manifestations of Antiphospholipid Syndrome—A Narrative Review. Brain Sci. 2022; 12(1): 1–15. DOI: 10.3390/brainsci12010091
    Back to article
  106. 106Milanov I, Bogdanova D. Antiphospholipid syndrome and dystonia-parkinsonism. A case report. Park Relat Disord. 2001; 7(2): 139–41. DOI: 10.1016/S1353-8020(00)00025-0
    Back to article
  107. 107Dietiker C, Clelland C, Gupta S, Richie M, Shah M, Bledsoe I. (San Francisco, CA USA). Antiphospholipid syndrome presenting with craniocervical Dystonia: A case study. Available from: https://www.mdsabstracts.org/abstract/antiphospholipid-syndrome-presenting-with-craniocervical-dystonia-a-case-study/.
    Back to article
  108. 108Angelini L, Rumi V, Nardocci N, Combi ML, Bruzzone MG, Pellegrini G. Hemidystonia symptomatic of primary antiphospholipid syndrome in childhood. Mov Disord. 1993; 8(3): 383–6. DOI: 10.1002/mds.870080327
    Back to article
  109. 109Chen WH, Chen CH, Chui C, Lui CC, Chen CJ, Yin HL. Antiphospholipid antibodies and cerebellar ataxia: A clinical analysis and literature review. Neuroimmunomodulation. 2014; 21(6): 283–90. DOI: 10.1159/000354614
    Back to article
  110. 110Shpiner DS, Dixon C, Ortega MR, Moore H. Movement Disorders in Antiphospholipid Syndrome & Systemic Lupus Erythematosus.
    Back to article
  111. 111Carecchio M, Comi C, Varrasi C, Stecco A, Sainaghi PP, Bhatia K, et al. Complex movement disorders in primary antiphospholipid syndrome: A case report. J Neurol Sci [Internet]. 2009; 281(1–2): 101–3. DOI: 10.1016/j.jns.2009.03.011
    Back to article
  112. 112Leal Rato M, Bandeira M, Romão VC, Aguiar de Sousa D. Neurologic Manifestations of the Antiphospholipid Syndrome — an Update. Curr Neurol Neurosci Rep. 2021; 21(8). DOI: 10.1007/s11910-021-01124-z
    Back to article
  113. 113Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol [Internet]. 2009; 8(2): 192–204. DOI: 10.1016/S1474-4422(09)70015-8
    Back to article
  114. 114Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behcet’s disease: Evaluation of 200 patients. Brain. 1999; 122(11): 2171–81. DOI: 10.1093/brain/122.11.2171
    Back to article
  115. 115Houman MH, Bellakhal S, Salem T Ben, Hamzaoui A, Braham A, Lamloum M, et al. Characteristics of neurological manifestations of Behçet’s disease: A retrospective monocentric study in Tunisia. Clin Neurol Neurosurg [Internet]. 2013; 115(10): 2015–8. DOI: 10.1016/j.clineuro.2013.06.009
    Back to article
  116. 116Tae-Ho G, Kim Y-In, Seong-Min P, Kim J-S. Paroxysmal Focal Dystonia in Neuro-Behcet by a Small Ipsilateral Thalamic-Lesion. European Neurology; Basel Vol. 47, Iss. 3, (Mar 2002): 183–4. Available from: https://www.proquest.com/openview/e4bf20614e4814d53771ee88a44f253c/1?pq-origsite=gscholar&cbl=41501.
    Back to article
  117. 117Saaf S, El Yacoubi Z, Lhassani S, Mimouni Y, Hakimi M, El Azhari M, Hazim A, Aasfara J, Ouhabi H. (casablanca M.) Hemibody dystonia secondary to Neurobehçet disease: a case report. Available from: https://www.mdsabstracts.org/abstract/hemibody-dystonia-secondary-to-neurobehcet-disease-a-case-report/.
    Back to article
  118. 118Quartarone A, Ruge D. How many types of dystonia? Pathophysiological considerations. Front Neurol. 2018; 9(FEB): 1–9. DOI: 10.3389/fneur.2018.00012
    Back to article
  119. 119Kilic-Berkmen G, Scorr LM, Rosen A, Wu E, Freeman A, Silver M, et al. Thyroid disease in cervical dystonia. Park Relat Disord. 2023; 107: 1–6. DOI: 10.1016/j.parkreldis.2022.105274
    Back to article
  120. 120Scorr LM, Kilic-Berkmen G, Sutcliffe DJ, Dinasarapu AR, McKay JL, Bagchi P, et al. Exploration of potential immune mechanisms in cervical dystonia. Park Relat Disord. 2024; 122. DOI: 10.1016/j.parkreldis.2024.106036
    Back to article
  121. 121Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012; 135(5): 1606–21. DOI: 10.1093/brain/aws092
    Back to article
  122. 122Akopian G, Crawford C, Beal MF, Cappelletti M, Jakowec MW, Petzinger GM, et al. Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia. J Neurosci. 2008; 28(38): 9585–97. DOI: 10.1523/JNEUROSCI.5698-07.2008
    Back to article
  123. 123Madeo G, Pisani A. Pathophysiology of Dystonia. Handb Behav Neurosci. 2016; 24: 929–50. DOI: 10.1016/B978-0-12-802206-1.00047-7
    Back to article
  124. 124Tisavipat N, Chang BK, Ali F, Pittock SJ, Kammeyer R, Declusin A, et al. Subacute Horizontal Diplopia, Jaw Dystonia, and Laryngospasm. Neurol Neuroimmunol neuroinflammation. 2023; 10(4): 0–5. DOI: 10.1212/NXI.0000000000200128
    Back to article
  125. 125Fueyo J, Ferrer I, Valldeoriola F, Graus F. The expression of a neuronal nuclear antigen (Ri) recognized by the human anti-Ri autoantibody in the developing rat nervous system. Available from: https://www.sciencedirect.com/science/article/abs/pii/030439409390580E?via%3Dihub.
    Back to article
  126. 126Lemos JC, Friend DM, Kaplan AR, Shin JH, Rubinstein M, Kravitz A V., et al. Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling. Neuron [Internet]. 2016; 90(4): 824–38. DOI: 10.1016/j.neuron.2016.04.040
    Back to article
  127. 127Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: A review of Sydenham chorea and beyond. Acta Physiol. 2016; 216(1): 90–100. DOI: 10.1111/apha.12614
    Back to article
  128. 128Gao Y, Li H, Luo H, Ni Y, Feng Y, He L, et al. Purified Serum IgG from a Patient with Anti-IgLON5 Antibody Cause Long-Term Movement Disorders with Impaired Dopaminergic Pathways in Mice. Biomedicines. 2023; 11(9). DOI: 10.3390/biomedicines11092483
    Back to article
  129. 129Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: A critical review of the literature. Brain Pathol. 2013; 23(6): 661–83. DOI: 10.1111/bpa.12084
    Back to article
  130. 130Sturchio A, Dwivedi AK, Gastaldi M, Grimberg MB, Businaro P, Duque KR, et al. Movement disorders associated with neuronal antibodies: a data-driven approach. J Neurol [Internet]. 2022; 269(7): 3511–21. DOI: 10.1007/s00415-021-10934-7
    Back to article
DOI: https://doi.org/10.5334/tohm.915 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: May 5, 2024
Accepted on: Nov 16, 2024
Published on: Dec 6, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
dystonia,
autoimmune encephalitis,
autoimmune dystonia

© 2024 Debayan Dutta, Ravi Yadav, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 14 (2024): Issue 1Next article